Securities Information

Cyprotex is a UK incorporated entity whose main operations are based in the UK and its shares trade on the AIM platform of the LSE.

The number of Cyprotex Securities in issue, as at 18th August 2010, is 223,687,485 ordinary shares of 0.1p each. None of those shares are held in Treasury and all shares, excluding those held by directors, Octopus Investments Nominees Limited and Intercapital Private Group Ltd (which represent 15.69% of the issued share capital of the company) are in public hands (as defined by the AIM rules).

There are no restrictions on the transfer of Cyprotex shares.

As of 18th August 2010, the following held shareholdings in excess of 3%:

- Douglas Bates (27,668,719 - 12.37%)

- Intercapital Private Group Ltd (27,024,465 - 12.08%)

- Katya Tsaioun (24,133,006 - 10.79%)

- R. J. Koch (16,748,868 - 7.49%)

- D. Leahy (10,401,600 - 4.65%)

- G.L.A. Dow (9,065,727 - 4.05%)

- R. Sneller (9,000,000 - 4.02%)

- Octopus Investments Nominees Limited (8,085,000 - 3.61%)

- R. Long (8,000,000 - 3.58%)

As of 18 August 2010, the directorate shareholdings were:

- S. Harris (1,507,142 - 0.67%)

- A. D. Baxter (1,067,685 - 0.48%)

- J. Dootson (589,285 - 0.26%)

- Katya Tsaioun (24,133,006 - 10.79%)

- Douglas Bates (27,668,719 - 12.37%)

The above disclosures are in compliance with AIM Rule 26